{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:13:22Z","timestamp":1790766802019,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 serum samples. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU\/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.<\/jats:p>","DOI":"10.1038\/s41541-022-00586-7","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T06:03:15Z","timestamp":1672380195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-5003","authenticated-orcid":false,"given":"Trung The","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline Benno","family":"Vaage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adity","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-2116","authenticated-orcid":false,"given":"Lisa","family":"Tietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Kolderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1725-4571","authenticated-orcid":false,"given":"Aina","family":"Anthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-9804","authenticated-orcid":false,"given":"Marton","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro","family":"Nygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-8410","authenticated-orcid":false,"given":"Andreas","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Sofie","family":"Nissen-Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Magnus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lill","family":"Trogstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Mjaaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"S\u00f8raas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Midtvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-1769","authenticated-orcid":false,"given":"Anders","family":"\u00c5sberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Barratt-Due","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7118-5127","authenticated-orcid":false,"given":"Asle W.","family":"Medhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte Lie","family":"H\u00f8ivik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi Fuglaas","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reidun","family":"Dahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Stien","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grete Birkeland","family":"Kro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-4078","authenticated-orcid":false,"given":"Rebecca J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-3422","authenticated-orcid":false,"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-1616","authenticated-orcid":false,"given":"Nina","family":"Langeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Melum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone Lise","family":"\u00c5vitsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Wiencke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-5022","authenticated-orcid":false,"given":"Jan Cato","family":"Holter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-3654","authenticated-orcid":false,"given":"Ludvig A.","family":"Munthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-3162","authenticated-orcid":false,"given":"Gunnveig","family":"Gr\u00f8deland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Terje","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-5768","authenticated-orcid":false,"given":"John Torgils","family":"Vaage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fridtjof","family":"Lund-Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"586_CR1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"586_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"586_CR3","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"586_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"586_CR5","doi-asserted-by":"publisher","unstructured":"Nguyen, D. et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill 26, https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.27.2100568 (2021).","DOI":"10.2807\/1560-7917.ES.2021.26.27.2100568"},{"key":"586_CR6","doi-asserted-by":"publisher","unstructured":"Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med., https:\/\/doi.org\/10.1038\/s41591-022-01721-6 (2022).","DOI":"10.1038\/s41591-022-01721-6"},{"key":"586_CR7","doi-asserted-by":"publisher","first-page":"113851","DOI":"10.1016\/j.ijheh.2021.113851","volume":"238","author":"TT Brehm","year":"2021","unstructured":"Brehm, T. T. et al. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. Int J. Hyg. Environ. Health 238, 113851 (2021).","journal-title":"Int J. Hyg. Environ. Health"},{"key":"586_CR8","doi-asserted-by":"publisher","unstructured":"Roltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell, https:\/\/doi.org\/10.1016\/j.cell.2022.01.018 (2022).","DOI":"10.1016\/j.cell.2022.01.018"},{"key":"586_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"586_CR10","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e1021 (2020).","journal-title":"Cell"},{"key":"586_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463\u2013476.e466 (2021).","journal-title":"Cell Host Microbe"},{"key":"586_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"586_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"key":"586_CR14","doi-asserted-by":"publisher","unstructured":"Abe, K. T. et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 5, https:\/\/doi.org\/10.1172\/jci.insight.142362 (2020).","DOI":"10.1172\/jci.insight.142362"},{"key":"586_CR15","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"586_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41586-021-03807-6","volume":"597","author":"TN Starr","year":"2021","unstructured":"Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97\u2013102 (2021).","journal-title":"Nature"},{"key":"586_CR17","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.abj4176","volume":"373","author":"A Pegu","year":"2021","unstructured":"Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 373, 1372\u20131377 (2021).","journal-title":"Science"},{"key":"586_CR18","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S2666-5247(21)00307-4","volume":"3","author":"F Zhu","year":"2022","unstructured":"Zhu, F. et al. WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. Lancet Microbe 3, e81\u2013e82 (2022).","journal-title":"Lancet Microbe"},{"key":"586_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23473-6","volume":"12","author":"M Becker","year":"2021","unstructured":"Becker, M. et al. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nat. Commun. 12, 3109 (2021).","journal-title":"Nat. Commun."},{"key":"586_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10987-2","volume":"12","author":"D Junker","year":"2022","unstructured":"Junker, D. et al. COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants. Sci. Rep. 12, 7168 (2022).","journal-title":"Sci. Rep."},{"key":"586_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457\u2013466.e454 (2022).","journal-title":"Cell"},{"key":"586_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cell.2022.01.006","volume":"185","author":"DR Wesemann","year":"2022","unstructured":"Wesemann, D. R. Omicron\u2019s message on vaccines: boosting begets breadth. Cell 185, 411\u2013413 (2022).","journal-title":"Cell"},{"key":"586_CR23","doi-asserted-by":"publisher","first-page":"964525","DOI":"10.3389\/fimmu.2022.964525","volume":"13","author":"A S\u00f8raas","year":"2022","unstructured":"S\u00f8raas, A. et al. Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity. Front Immunol. 13, 964525 (2022).","journal-title":"Front Immunol."},{"key":"586_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","volume":"596","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410\u2013416 (2021).","journal-title":"Nature"},{"key":"586_CR25","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 385, e84 (2021).","journal-title":"N. Engl. J. Med."},{"key":"586_CR26","doi-asserted-by":"publisher","unstructured":"Jena, A. et al. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., https:\/\/doi.org\/10.1016\/j.cgh.2022.02.030 (2022).","DOI":"10.1016\/j.cgh.2022.02.030"},{"key":"586_CR27","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jhep.2021.08.008","volume":"75","author":"PJ Thuluvath","year":"2021","unstructured":"Thuluvath, P. J., Robarts, P. & Chauhan, M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J. Hepatol. 75, 1434\u20131439 (2021).","journal-title":"J. Hepatol."},{"key":"586_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"586_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2022","unstructured":"Schmidt, F. et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N. Engl. J. Med. 386, 599\u2013601 (2022).","journal-title":"N. Engl. J. Med."},{"key":"586_CR30","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.immuni.2022.04.002","volume":"55","author":"A Sokal","year":"2022","unstructured":"Sokal, A. et al. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. Immunity 55, 1096\u20131104.e1094 (2022).","journal-title":"Immunity"},{"key":"586_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"586_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"586_CR33","doi-asserted-by":"publisher","first-page":"e0024721","DOI":"10.1128\/Spectrum.00247-21","volume":"9","author":"T Perkmann","year":"2021","unstructured":"Perkmann, T. et al. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol. Spectr. 9, e0024721 (2021).","journal-title":"Microbiol. Spectr."},{"key":"586_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","volume":"599","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114\u2013119 (2021).","journal-title":"Nature"},{"key":"586_CR35","doi-asserted-by":"publisher","unstructured":"Konig, M. et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J. Neurol. Neurosurg. Psychiatry, jnnp-2021-327612, https:\/\/doi.org\/10.1136\/jnnp-2021-327612 (2021).","DOI":"10.1136\/jnnp-2021-327612"},{"key":"586_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jamaneurol.2021.5109","volume":"79","author":"M Konig","year":"2022","unstructured":"Konig, M. et al. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. JAMA Neurol. 79, 307\u2013309 (2022).","journal-title":"JAMA Neurol."},{"key":"586_CR37","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1097\/TP.0000000000003856","volume":"105","author":"K Midtvedt","year":"2021","unstructured":"Midtvedt, K. et al. Low immunization rate in kidney transplant recipients also after dose 2 of the BNT162b2 vaccine: continue to keep your guard up! Transplantation 105, e80\u2013e81 (2021).","journal-title":"Transplantation"},{"key":"586_CR38","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","volume":"397","author":"PA Kristiansen","year":"2021","unstructured":"Kristiansen, P. A. et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 397, 1347\u20131348 (2021).","journal-title":"Lancet"},{"key":"586_CR39","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","volume":"3","author":"I Knezevic","year":"2022","unstructured":"Knezevic, I. et al. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe 3, e235\u2013e240 (2022).","journal-title":"Lancet Microbe"},{"key":"586_CR40","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."},{"key":"586_CR41","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"586_CR42","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41592-018-0179-8","volume":"15","author":"K Sikorski","year":"2018","unstructured":"Sikorski, K. et al. A high-throughput pipeline for validation of antibodies. Nat. Methods 15, 909\u2013912 (2018).","journal-title":"Nat. Methods"},{"key":"586_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1074\/mcp.M800171-MCP200","volume":"8","author":"W Wu","year":"2009","unstructured":"Wu, W. et al. Antibody array analysis with label-based detection and resolution of protein size. Mol. Cell Proteom. 8, 245\u2013257 (2009).","journal-title":"Mol. Cell Proteom."},{"key":"586_CR44","doi-asserted-by":"publisher","first-page":"100014","DOI":"10.1016\/j.lanepe.2020.100014","volume":"3","author":"K Kuwelker","year":"2021","unstructured":"Kuwelker, K. et al. Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: a case-ascertained study. Lancet Reg. Health Eur. 3, 100014 (2021).","journal-title":"Lancet Reg. Health Eur."}],"updated-by":[{"DOI":"10.1038\/s41541-023-00600-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000}}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00586-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T02:03:27Z","timestamp":1674698607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00586-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1500697\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1500697\/v2","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"12 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41541-023-00600-6","URL":"https:\/\/doi.org\/10.1038\/s41541-023-00600-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Trung The Tran has nothing to disclose. Eline Benno Vaage has nothing to disclose. Adi Mehta has nothing to disclose. Adity Chopra has nothing to disclose. Lisa Tietze has nothing to disclose. Anette Kolderup has received support from South-Eastern Norway Regional Health Authority (Grant no 10357 and 2021069. The payments were made to the institution, Oslo University Hospital, and covered salary and consumables). Aina Karen Anthi has received support from South-Eastern Norway Regional Health Authority (Grant no 2019084. The payments were made to the institution, Oslo University Hospital, and covered salary and consumables). M. Konig has received speaker honoraria from Novartis, Biogen, Sanofi, and Merck and support from Coalition for Epidemic Preparedness Innovations (CEPI) through Oslo University Hospital. Gro Nygard has received support from Coalition for Epidemic Preparedness Innovations (CEPI) through Oslo University Hospital. Andreas Lind has nothing to disclose. Fredrik Muller has nothing to disclose. Lise Sofie Haug Nissen-Meyer has nothing to disclose. Per Magnus has received support from Norwegian Institute of Public Health for collection of blood samples in NorFlu and MoBa since 2020. Lill-Iren Schou Trogstad has received support from Norwegian Institute of Public Health for collection of blood samples in NorFlu and MoBa since 2020. Siri Mjaaland has nothing to disclose. Arne Soraas has received support from Norwegian Cancer Association, Norwegian research Council, and Southeastern Norway Health Authority. Karsten Midtvedt has nothing to disclose. Anders Asberg has received payment to the institution from Sandos and Orifarm. Andreas Barratt-Due has nothing to disclose. Asle Wilhelm Medhus has received a grant from Takeda (Grant to a research-initiated project, payment to institution). Marte Lie Hoivik has received research grants to the institution from Pfizer, Janssen, Takeda, Ferring, Tillotts and has participated on a Data Safety Monitoring Board or Advisory Board at Takeda with personal fees. Knut Lundin has nothing to disclose. Randi Fuglaas Karlsen has nothing to disclose. Reidun Dahle has nothing to disclose. Karin Danielsson has nothing to disclose. Kristine Stien Thomassen has nothing to disclose. Grete Birkeland Kro has nothing to disclose. Rebecca Jane Cox has nothing to disclose. Fan Zhou has nothing to disclose. Nina Langeland has nothing to disclose. Pal Aukrust has received support from Klinbeforsk. grants for COVID-19 research 2020. Espen Melum has nothing to disclose. Tone Lise \u00c5vitsland has nothing to disclose. Kristine Wiencke has nothing to disclose. Jan Cato Holter has received support from Oslo University hospital, Research Council of Norway (Grant no 312780), and Philantropic donation from Vivaldi Invest A\/A owned by Jon Steohenson von Tetzchner. Ludvig Andre Munthe has received support from CEPI (Oslo University Hospital, University of Oslo), funding from University of Oslo, RCN, Norwegian Cancer Society, Health South East Health Research Funds (Stiftelsen KG Jebsen Grant 19), consulting fees in 20201: Astrazeneca for a panel discussing options for Long-Acting anti-SARS-CoV-2 Biologic AZD 7442, 4-time slots, < 1000USD, and payment for expert testimony in 20201 (Part of the expert panel for Norwegian Medicines Agency on vaccinology and associated topics, salary 1500USD and part of the expert panel for Norwegian Institute of Public Health for Norwegian Corona Vaccination Program. 8 meetings. Pro Bono). Gunnveig Grodeland has received support from South-Eastern Norway Regional Health Authority, grants from the Research Council of Norway and EU-Horizon 2020, consulting fees from the Norwegian System of Compensation to Patients, honoraria from Bayer, ThermoFisher, and Saofi. She has also participated on the Data Safety Monitoring Board or Advisory Board with AstraZeneca. Jan Terje Andersen has received support from South-Eastern Norway Regional Health Authority (Grant no 10357 and 2021069. The payments were made to the institution, Oslo University Hospital, and covered salary and consumables) and from Juni Andrell, Stockholm University, Sweden (cDNA encoding 8xHis-tagged HexaPro spike protein and 6xHis-tagged receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan, in the expression plasmids p\u03b1H and pCAGGS, respectively. He has collaborated with Roche, Tillotts Pharma, SJJ Solutions, Argenx, and Nordic Nanovector. Not directly related to the work of this manuscript. John Torgils Vaage has nothing to disclose. Fridtjof Lund-Johansen has received support from the South-Eastern Norway Regional Health Authority grant for developing COVID-19 serology. He has also received support from The Coalition for Epidemic Preparedness and Innovation (CEPI), a grant to monitor vaccine responses in patients on immunosuppressive therapy. The grants were paid to the institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}